PDCD1 and urothelial carcinoma: In a meta-analysis of 5722 patients, data showed a higher incidence of nephrotoxicity associated with PD-1 mAb and that patients with urothelial carcinoma treated with pembrolizumab were more likely to develop kidney damage (113).